베인은 홈페이지 기능 및 성능 개선을 위해 쿠키를 사용합니다. 이와 관련된 더 많은 정보는 개인정보 메뉴에서 확인하실 수 있습니다. 이 웹사이트를 계속 사용하시면 쿠키 사용에 동의하신 것으로 간주됩니다. 

In Vivo

Biopharma Strategies: To Outperform in Pharma, Go Deep—Not Broad

Biopharma Strategies: To Outperform in Pharma, Go Deep—Not Broad

The most successful pharma companies aren't winning due to absolute scale. Instead, they succeed thanks to their leadership in a few clearly defined product categories.

  • 2016년7월26일
  • 읽기 소요시간

Article

Biopharma Strategies: To Outperform in Pharma, Go Deep—Not Broad

This article was originally published in In Vivo.

The world's most successful pharma companies aren't winning on the basis of absolute scale; they succeed instead thanks to their leadership in a few clearly defined product categories. That approach delivers outsized returns, while helping firms navigate a changing health care landscape where payers and providers increasingly demand evidence of treatment efficacy.

  • Category leaders are those firms that employ a common set of capabilities to develop products that serve a defined set of end-users and often exist without common competitive class. The products are bought using a common purchasing process managed by common stakeholders.
  • The key to understanding category leadership is to view categories through the eyes of the customer—patients, prescribing physicians and payers.
  • Current industry trends play to the strengths of category leaders. Payers and providers are demanding evidence of efficacy, creating new hurdles for drug approval, and category leaders are the best positioned to deliver compelling evidence.
  • The rise of drugs prescribed by specialists instead of primary care physicians also favors pharma companies with deep networks and strong relationships within the specialty.
태그

베인에 궁금하신 점이 있으신가요?

베인은 글로벌 리더들이 중요한 이슈를 해결하고 기회를 놓치지 않도록 지원합니다. 고객사와 협력하여 지속되는 변화와 성과를 창출합니다.